背景:慢性高血糖引发生物分子的非酶糖基化,导致糖基化终产物的产生,导致多种微血管和大血管并发症。因此,新的发现,有效,和安全的抗糖化剂是一个重要的需要。治疗糖尿病的最佳选择之一是使用补充和替代药物疗法。因此,本研究旨在评估八角树乙醇提取物的抗糖基化活性。f.(八角,一种经常使用的香料和重要的药用植物)。
方法:八角树乙醇提取物的抗糖基化活性。通过使用体外和体内测定来确定f.HSA-果糖糖基化模型用于评估蛋白质糖基化的体外抑制作用,通过SDS聚丙烯酰胺凝胶电泳评估另外交联的AGEs(通过溶菌酶与果糖孵育形成)。双重抑制机制,即,抗氧化和金属螯合活性,还通过使用DPPH进行了评估,ABTS,和Fe(II)-螯合测定。还进行了I.verum提取物的急性毒性(通过施用不同剂量,即2,000、1,500、1,000和500mg/kg体重)。最后,通过在链脲佐菌素诱导的糖尿病大鼠中施用I.verum提取物7周来评估体内抗糖基化潜力。
结果:在HSA-果糖糖基化模型中,木耳提取物具有良好的抑制活性,IC50值为0.11±0.001mg/mL,与标准抑制剂相比,芦丁(IC50=0.02±0.01mg/mL)。I.verum提取物对DPPH具有抑制活性,和ABTS自由基清除测定法,IC50值为130±1.0和57±2.0μg/mL,分别,而在Fe+2螯合试验中发现它是无活性的。发现提取物是无毒的,降低升高的血糖,尿素,脂质,肝功能参数,和链脲佐菌素诱导的糖尿病大鼠的肾脏AGEs水平。
结论:这些结果表明,补充I.verum可能有助于减轻AGEs的负担,并可能有预防糖尿病相关并发症的潜力。
BACKGROUND: Chronic hyperglycemic triggers the non-enzymatic glycation of biomolecules, resulting in the production of advanced glycation endproducts, that lead to several micro- and macrovascular complications. Therefore, the discovery of new, effective, and safe anti-glycation agents is an important need. One of the best choices for the management of diabetes is to use complementary and alternative medicinal therapies. Therefore, the present study was designed to evaluate the anti-glycation activity of ethanolic extract of
Illicium verum Hook. f. (Star anise, a frequently used spice and medicinally important herb).
METHODS: The anti-glycation activity of ethanolic extract of
Illicium verum Hook. f. was determined by using both in-vitro and in-vivo assays. HSA-fructose glycation model was employed to assess the in-vitro inhibition of protein glycation, additionally cross-linked AGEs (formed by incubating lysozyme with fructose) were assessed by SDS polyacrylamide gel electrophoresis. Dual inhibitory mechanisms, i.e., antioxidant and metal chelating activities, were also evaluated by using DPPH, ABTS, and Fe (II)-chelation assays. Acute toxicity of I. verum extract was also performed (by administrating different doses i.e. 2,000, 1,500, 1,000, and 500 mg/kg of body weight). Finally, in-vivo anti-glycation potential was evaluated by 7 weeks of administration of I. verum extract in streptozotocin-induced diabetic rats.
RESULTS: In HSA-fructose glycation model, extract of I. verum showed a good inhibitory activity with IC50 value of 0.11±0.001 mg/mL, as compared to the standard inhibitor, rutin (IC50 = 0.02±0.01 mg/mL). Extract of I. verum showed inhibitory activity in DPPH, and ABTS radical scavenging assays with IC50 values of 130±1.0, and 57±2.0 μg/mL, respectively, while it was found to be inactive in the Fe+2-chelation assay. The extract was found to be non-toxic, and reduce the elevated blood glucose, urea, lipid, liver function parameters, and renal AGEs levels in streptozotocin-induced diabetic rats.
CONCLUSIONS: These results suggest that I. verum supplementation might help to reduce the burden of AGEs, and may have potential in preventing diabetes-associated complications.